Jun 28, 2026 – 4.00pmJeremy Levin says an age of distrust is killing off the biotech sector. He would know. Levin is the chairman of Opthea, the ASX-listed healthcare hopeful where late-stage clinical trials of the company’s vision-impairment treatment flopped spectacularly last year.Now he is back, asking investors to give the company a second chance as it pivots from trying to cure a chronic eye disorder that causes blurred vision to combatting a rare lung disease called lymphangioleiomyomatosis.Subscribe to gift this articleGift 5 articles to anyone you choose each month when you subscribe.Subscribe nowAlready a subscriber? Michael SmithHealth editorMichael Smith is the health editor for The Australian Financial Review. He is based in Sydney.Fetching latest articles